LIM kinase inhibitor Pyr1 reduces the growth and metastatic load of breast cancers

Cancer Research

Volumn 76, Issue 12, 2016, Pages 3541-3552

  Prunier, Chloé ^a,f   Josserand, Véronique ^a   Vollaire, Julien ^a   Beerling, Evelyne ^b   Petropoulos, Christos ^a   Destaing, Olivier ^a   Montemagno, Christopher ^a   Hurbin, Amandine ^a   Prudent, Renaud ^a   De Koning, Leanne ^c   Kapur, Reuben ^d   Cohen, Pascale A ^e   Albiges Rizo, Corinne ^a   Coll, Jean Luc ^a   Van Rheenen, Jacco ^b   Billaud, Marc ^a,g   Lafanechère, Laurence ^a,h  

^a UNIV GRENOBLE ALPES   (France)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INSTITUT CURIE   (France)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITÉ LYON 1   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g CNRS   (France)

^h INSTITUTE FOR ADVANCED BIOSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PACLITAXEL; PYR1; UNCLASSIFIED DRUG; 9-BENZOYLOXY-5,11-DIMETHYL-2H,6H-PYRIDO(4,3-B)CARBAZOL-1-ONE; CARBAZOLE DERIVATIVE; LIM KINASE; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; FEMALE; FILOPODIUM; IN VITRO STUDY; IN VIVO STUDY; INTRAVITAL MICROSCOPY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR INVASION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; METASTASIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HUMANS; LIM KINASES; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS;

EID: 84976869371     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1864     Document Type: Article

References (50)

1. Scott RW, Olson MF. LIM kinases: function, regulation and association with human disease. J Mol Med 2007;85:555-68.
2. Prudent R, Vassal-Stermann E, Nguyen CH, Pillet C, Martinez A, Prunier C, et al. Pharmacological inhibition of LIM kinase stabilizes microtubules and inhibits neoplastic growth. Cancer Res 2012;72:4429-39.
3. Gorovoy M, Niu J, Bernard O, Profirovic J, Minshall R, Neamu R, et al. LIM kinase 1 coordinates microtubule stability and actin polymerization in human endothelial cells. J Biol Chem 2005;280:26533-42.
4. Mardilovich K, Gabrielsen M, McGarry L, Orange C, Patel R, Shanks E, et al. Elevated LIM kinase 1 in nonmetastatic prostate cancer reflects its role in facilitating androgen receptor nuclear translocation. Mol Cancer Ther 2015;14:246-58.
5. Bhardwaj A, Srivastava SK, Singh S, Arora S, Tyagi N, Andrews J, et al. CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1. Oncotarget 2014;5:11490-500.
6. Pleines I, Dütting S, Cherpokova D, Eckly A, Meyer I, Morowski M, et al. Defective tubulin organization and proplatelet formation in murine megakaryocytes lacking Rac1 and Cdc42. Blood 2013;122:3178-87.
7. Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br J Pharmacol 2014;171:5507-23.
8. Prudnikova TY, Rawat SJ, Chernoff J. Molecular pathways: targeting the kinase effectors of RHO-family GTPases. Clin Cancer Res 2015;21:24-9
9. Mali RS, Kapur R. Targeting Rho associated kinases in leukemia and myeloproliferative neoplasms. Oncotarget 2012;3:909-10.
10. Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2:133-42.
11. Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK inhibition for cancer therapy. EMBO Rep 2012;13:900-8.
12. Manetti F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med Res Rev 2012;32:968-98.
13. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, Sahai E, et al. Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 2004;64:8585-94.
14. Okamoto I, Pirker C, Bilban M, Berger W, Losert D, Marosi C, et al. Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma. Neoplasia 2005;7:303-11.
15. Park J-B, Agnihotri S, Golbourn B, Bertrand KC, Luck A, Sabha N, et al. Transcriptional profiling of GBM invasion genes identifies effective inhibitors of the LIM kinase-Cofilin pathway. Oncotarget 2014;5:9382-95.
16. Davila M, Frost AR, Grizzle WE, Chakrabarti R. LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem 2003;278:36868-75.
17. Ahmed T, Shea K, Masters JRW, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal 2008;20:1320-8.
18. McConnell BV, Koto K, Gutierrez-Hartmann A. Nuclear and cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer 2011;10:75.
19. Bagheri-Yarmand R, Mazumdar A, Sahin AA, Kumar R. LIM kinase 1 increases tumor metastasis of human breast cancer cells via regulation of the urokinase-type plasminogen activator system. Int J Cancer 2006;118:2703-10.
20. Shibue T, Brooks MW, Weinberg RA. An integrin-linked machinery of cytoskeletal regulation that enables experimental tumor initiation and metastatic colonization. Cancer Cell 2013;24:481-98.
21. Manetti F. Recent findings confirm LIM domain kinases as emerging target candidates for cancer therapy. Curr Cancer Drug Targets 2012;12:543-60.
22. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, Penhallow B, et al. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther 2008;7:3490-8.
23. Harrison BA, Whitlock NA, Voronkov MV, Almstead ZY, Gu KJ, Mabon R, et al. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J Med Chem 2009;52:6515-8.
24. Harrison BA, Almstead ZY, Burgoon H, Gardyan M, Goodwin NC, Healy J, et al. Discovery and development of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of glaucoma. ACS Med Chem Lett 2015;6:84-8.
25. Ohashi K, Sampei K, Nakagawa M, Uchiumi N, Amanuma T, Aiba S, et al. Damnacanthal, an effective inhibitor of LIM-kinase, inhibits cell migration and invasion. Mol Biol Cell 2014;25:828-40.
26. Mashiach-Farkash E, Rak R, Elad-Sfadia G, Haklai R, Carmeli S, Kloog Y, et al. Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton. Oncotarget 2012;3:629-39.
27. Rak R, Haklai R, Elad-Tzfadia G, Wolfson HJ, Carmeli S, Kloog Y. Novel LIMK2 Inhibitor Blocks Panc-1 Tumor Growth in a mouse xenograft model. Oncoscience 2014;1:39-48.
28. Yin Y, Zheng K, Eid N, Howard S, Jeong J-H, Yi F, et al. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors. J Med Chem 2015;58:1846-61.
29. Nanni P, de Giovanni C, Lollini PL, Nicoletti G, Prodi G. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metastasis 1983;1:373-80.
30. Vendrell JA, Thollet A, Nguyen NT, Ghayad SE, Vinot S, Bièche I, et al. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion. Cancer Res 2012;72:3593-606.
31. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR. Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. J Cell Sci 2009;122:3037-49.
32. Shibue T, Weinberg RA. Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci U S A 2009;106:10290-5.
33. Zomer A, Ellenbroek SIJ, Ritsma L, Beerling E, Vrisekoop N, Van Rheenen J. Intravital imaging of cancer stem cell plasticity in mammary tumors. Stem Cells 2013;31:602-6.
34. Yoshioka K, Foletta V, Bernard O, Itoh K. A role for LIM kinase in cancer invasion. Proc Natl Acad Sci U S A 2003;100:7247-52.
35. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer 2007;7:429-40.
36. Shibue T, Brooks MW, Inan MF, Reinhardt F, Weinberg RA. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov 2012;2:706-21.
37. Thollet A, Vendrell JA, Payen L, Ghayad SE, Ben Larbi S, Grisard E, et al. ZNF217 confers resistance to the pro-apoptotic signals of paclitaxel and aberrant expression of Aurora-A in breast cancer cells. Mol Cancer 2010;9:291.
38. Flores ML, Castilla C, Ávila R, Ruiz-Borrego M, Sáez C, Japón MA. Paclitaxel sensitivity of breast cancer cells requires efficient mitotic arrest and disruption of Bcl-xL/Bak interaction. Breast Cancer Res Treat 2012;133:917-28.
39. Janát-Amsbury MM, Yockman JW, Lee M, Kern S, Furgeson DY, Bikram M, et al. Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model. Mol Ther 2004;9:829-36.
40. Riondel J, Jacrot M, Picot F, Beriel H, Mouriquand C, Potier P. Therapeutic response to taxol of six human tumors xenografted into nude mice. Cancer Chemother Pharmacol 1986;17:137-42.
41. Mardilovich K, Baugh M, Crighton D, Kowalczyk D, Gabrielsen M, Munro J, et al. LIM kinase inhibitors disrupt mitotic microtubule organization and impair tumor cell proliferation. Oncotarget 2015;6:38469-86.
42. Destaing O, Planus E, Bouvard D, Oddou C, Badowski C, Bossy V, et al. β1A integrin is a master regulator of invadosome organization and function. Mol Biol Cell 2010;21:4108-19.
43. Bravo-Cordero JJ, Magalhaes MAO, Eddy RJ, Hodgson L, Condeelis J. Functions of cofilin in cell locomotion and invasion. Nat Rev Mol Cell Biol 2013;14:405-15.
44. Entenberg D, Kedrin D, Wyckoff J, Sahai E, Condeelis J, Segall JE. Imaging tumor cell movement in vivo. Curr Protoc Cell Biol 2013;Chapter 19: Unit19.7.
45. Beerling E, Ritsma L, Vrisekoop N, Derksen PWB, van Rheenen J. Intravital microscopy: new insights into metastasis of tumors. J Cell Sci 2011;124:299-310.
46. Bunnage ME, Chekler ELP, Jones LH. Target validation using chemical probes. Nat Chem Biol 2013;9:195-9.
47. Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A, et al. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol 2006;173:395-404.
48. Etienne-Manneville S. Microtubules in cell migration. Annu Rev Cell Dev Biol 2013;29:471-99.
49. Wolf K, Friedl P. Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol 2011;21:736-44.
50. Gligorijevic B, Bergman A, Condeelis J. Multiparametric classification links tumor microenvironments with tumor cell phenotype. PLoS Biol 2014;12:e1001995.